SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

被引：0

作者：

Efe, Cumali ^{[1
]}

Tascilar, Koray ^{[2
,3
]}

Gerussi, Alessio ^{[4
,5
,6
]}

Bolis, Francesca ^{[4
,5
]}

Lammert, Craig ^{[7
]}

Ebik, Berat ^{[8
]}

Stattermayer, Albert Friedrich ^{[9
]}

Cengiz, Mustafa ^{[10
]}

Gokce, Dilara Turan ^{[11
]}

Cristoferi, Laura ^{[4
,5
,6
]}

Peralta, Mirta ^{[12
,13
]}

Massoumi, Hatef ^{[14
]}

Montes, Pedro ^{[15
]}

Cerda, Eira ^{[16
]}

Rigamonti, Cristina ^{[17
,18
]}

Yapali, Suna ^{[19
]}

Adali, Gupse ^{[20
]}

Caliskan, Ali Riza ^{[21
]}

Balaban, Yasemin ^{[22
]}

Eren, Fatih ^{[23
]}

Eskazan, Tugce ^{[24
]}

Barutcu, Sezgin ^{[25
]}

Lytvyak, Ellina ^{[26
,27
]}

Zazueta, Godolfino Miranda ^{[28
]}

Kayhan, Meral Akdogan ^{[10
]}

Heurgue-Berlot, Alexandra ^{[29
]}

De Martin, Eleonora ^{[30
]}

Yavuz, Ahmet ^{[31
]}

Biyik, Murat ^{[31
]}

Narro, Graciela Castro ^{[28
]}

Duman, Serkan ^{[32
]}

Hernandez, Nelia ^{[33
]}

Gatselis, Nikolaos K. ^{[34
,35
,36
]}

Aguirre, Jonathan ^{[37
]}

Idilman, Ramazan ^{[32
]}

Silva, Marcelo ^{[13
,38
]}

Mendizabal, Manuel ^{[13
,38
]}

Atay, Kadri ^{[39
]}

Guzelbulut, Fatih ^{[40
]}

Dhanasekaran, Renumathy ^{[41
]}

Montano-Loza, Aldo J. ^{[26
,27
]}

Dalekos, George N. ^{[34
,35
,36
]}

Ridruejo, Ezequiel ^{[13
,38
,42
]}

Invernizzi, Pietro ^{[4
,5
,6
]}

Wahlin, Staffan ^{[43
,44
]}

机构：

[1] Harran Univ Hosp, Dept Gastroenterol, Sanliurfa, Turkey

[2] Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Med Rheumatol & Immunol 3, Erlangen, Germany

[3] Univ Klinikum Erlangen, Erlangen, Germany

[4] Univ Milano Bicocca, Div Gastroenterol, Dept Med & Surg, Monza, Italy

[5] Univ Milano Bicocca, Ctr Autoimmune Liver Dis, Dept Med & Surg, Monza, Italy

[6] San Gerardo Hosp, European Reference Network Hepatol Dis ERN RARE L, Monza, Italy

[7] Univ Sch Med, Dept Med Indiana, Indianapolis, IN USA

[8] Gazi Yasargil Educ & Res Hosp, Dept Gastroenterol, Diyarbakir, Turkey

[9] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Vienna, Austria

[10] Gulhane Training & Res Hosp, Dept Gastroenterol, Ankara, Turkey

[11] Ankara City Hosp, Dept Gastroenterol, Ankara, Turkey

[12] Hosp Francisco J Muniz, Hepatol Sect, Buenos Aires, DF, Argentina

[13] Latin Amer Liver Res Educ & Awareness Network LAL, Pilar, Argentina

[14] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA

[15] Hosp Nacl Daniel A Carrion, Gastroenterol & Hepatol Unit, Callao, Peru

[16] Hosp Mil Cent Mexico, Hepatol Unit, Ciudad De Mexico, Mexico

[17] Univ Piemonte Orientale UPO, Dept Translat Med, Novara, Italy

[18] AOU Maggiore della Carita, Div Internal Med, Novara, Italy

[19] Acibadem Univ, Dept Gastroenterol, Sch Med, Istanbul, Turkey

[20] Umraniye Educ & Res Hosp, Dept Gastroenterol, Istanbul, Turkey

[21] Adiyaman Univ, Dept Gastroenterol, Adiyaman, Turkey

[22] Hacettepe Univ, Fac Med, Dept Gastroenterol, Ankara, Turkey

[23] Uludag Univ, Med Fac, Dept Gastroenterol, Bursa, Turkey

[24] Cerrahpa Sch Med, Dept Gastroenterol, Istanbul, Turkey

[25] Univ Gaziantep Med Fac, Dept Gastroenterol, Gaziantep, Turkey

[26] Univ Alberta, Div Gastroenterol, Edmonton, AB, Canada

[27] Univ Alberta, Liver Unit, Edmonton, AB, Canada

[28] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Gastroenterol Unit, Ciudad De Mexico, Mexico

[29] CHU Reims, Dept Hepatogastroenterol, Reims, France

[30] Univ Paris Saclay, Ctr Hepatobiliaire, INSERM Unit UMR 1193, FHU Hepatinov,Hop Paul Brousse, Paris, France

[31] Necmettin Erbakan Univ, Meram Sch Med, Div Gastroenterol, Konya, Turkey

[32] Ankara Univ, Dept Gastroenterol, Med Fac, Ankara, Turkey

[33] Univ Republica, Hosp Clin, Fac Med, Gastroenterol & Hepatol Unit, Montevideo, Uruguay

[34] Gen Univ Hosp Larissa, Natl Expertise Ctr Greece Autoimmune Liver Dis, Dept Med, Larisa, Greece

[35] Gen Univ Hosp Larissa, Natl Expertise Ctr Greece Autoimmune Liver Dis, Res Lab Internal Med, Larisa, Greece

[36] Gen Univ Hosp Larissa, European Reference Network Hepatol Dis ERN RARE L, Larisa, Greece

[37] Hosp Ngeles Pedregal, Hepatol Unit, Ciudad De Mexico, Mexico

[38] Hosp Univ Austral, Hepatol & Liver Transplant Unit, Pilar, Argentina

[39] Mardin State Hosp, Dept Gastroenterol, Mardin, Turkey

[40] Haydarpa Numune Educ & Res Hosp, Dept Gastroenterol, Istanbul, Turkey

[41] Stanford Univ, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA

[42] CEMIC, Ctr Educ Med & Invest Clin, Hepatol Sect, Dept Med, Buenos Aires, DF, Argentina

[43] Karolinska Inst, Dept Upper GI Dis, Hepatol Div, Stockholm, Sweden

[44] Karolinska Univ Hosp, Stockholm, Sweden

来源：

JOURNAL OF AUTOIMMUNITY | 2022年 / 132卷

关键词：

Liver failure; Breakthrough infection; Immunosuppression; Vaccine; Autoimmunity;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in pa-tients with AIH.

引用

页数：5

共 50 条

[1] SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis
Efe, Cumali
Tascilar, Koray
Gerussi, Alessio
Bolis, Francesca
Lammert, Craig
Ebik, Berat
Stattermayer, Albert Friedrich
Cengiz, Mustafa
Gokce, Dilara Turan
Cristoferi, Laura
Peralta, Mirta
Massoumi, Hatef
Montes, Pedro
Cerda, Eira
Rigamonti, Cristina
Yapali, Suna
Adali, Gupse
Caliskan, Ali Riza
Balaban, Yasemin
Eren, Fatih
Eskazan, Tugce
Barutcu, Sezgin
Lytvyak, Ellina
Zazueta, Godolfino Miranda
Kayhan, Meral Akdogan
Heurgue-Berlot, Alexandra
De Martin, Eleonora
Yavuz, Ahmet
Biyik, Murat
Narro, Graciela Castro
Duman, Serkan
Hernandez, Nelia
Gatselis, Nikolaos K.
Aguirre, Jonathan
Idilman, Ramazan
Silva, Marcelo
Mendizabal, Manuel
Atay, Kadri
Guzelbulut, Fatih
Dhanasekaran, Renumathy
Montano-Loza, Aldo J.
Dalekos, George N.
Ridruejo, Ezequiel
Invernizzi, Pietro
Wahlin, Staffan
JOURNAL OF AUTOIMMUNITY, 2022, 132
[2] Effects of SARS-CoV-2 Vaccination on Outcomes of COVID-19 in ESKD Patients on Dialysis
Miao, Jing
Olson, Elsa
Dillon, John J.
Zoghby, Ziad
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 891 - 891
[3] SARS-CoV-2 Vaccination in Patients with Cancer and COVID-19 in Mexico
Barrientos-Flores, Corazon
Vilar-Compte, Diana
Martinez-Rivera, Nancy
Villasenor-Echavarri, Rodrigo
Martin-Onraet, Alexandra
VACCINES, 2024, 12 (10)
[4] Autoimmune hepatitis triggered by SARS-CoV-2 vaccination
Vuille-Lessard, Elise
Montani, Matteo
Bosch, Jaume
Semmo, Nasser
JOURNAL OF AUTOIMMUNITY, 2021, 123
[5] Autoimmune hepatitis after SARS-CoV-2 vaccination
Ruiz, Sandra Diez
Castro, Raisa Quinones
Vega, Laura Alcoba
Izquierdo, Alia Martin
Puente, Isabel Gonzalez
Martin, Laura Rodriguez
Martin, Rodriguez
Rodriguez, Ruben Diez
Plaza, Francisco Jorquera
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2023, 115 (07)
[6] Effectiveness of two-dose COVID-19 vaccination against SARS-CoV-2 infection and severe outcomes in cancer patients
Lee, Hui-Eon
Jeong, Na-Young
Lim, Eunsun
Won, Heehyun
Kim, Jeong Ah
Kim, Chung-Jong
Choi, Nam-Kyong
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 174 - 174
[7] Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes
Lin, Dan-Yu
Gu, Yu
Xu, Yangjianchen
Wheeler, Bradford
Young, Hayley
Sunny, Shadia Khan
Moore, Zack
Zeng, Donglin
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (14): : 1415 - 1426
[8] COVID-19 in patients with multiple sclerosis despite SARS-CoV-2 vaccination
Mahadeen, A. Z.
Rose, D.
Carlson, A. K.
Planchon, S. M.
Sedlak, J.
Cohen, J. A.
Moss, B.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 794 - 795
[9] SARS-CoV-2 infection and COVID-19 vaccination in pregnancy
Victoria Male
Nature Reviews Immunology, 2022, 22 : 277 - 282
[10] SARS-CoV-2 infection and COVID-19 vaccination in pregnancy
Male, Victoria
NATURE REVIEWS IMMUNOLOGY, 2022, 22 (05) : 277 - 282

← 1 2 3 4 5 →